FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors
Leigh Marcus(Center for Drug Evaluation and Research), Steven J. Lemery(Center for Drug Evaluation and Research), Soma Ghosh(Center for Devices and Radiological Health), Reena Philip(Center for Devices and Radiological Health), Pamela Gallagher(Center for Devices and Radiological Health), Lisa Rodríguez(Center for Drug Evaluation and Research), Mengdie Yuan(Center for Drug Evaluation and Research), Martha Donoghue(Center for Drug Evaluation and Research), Marc R. Theoret(United States Food and Drug Administration), Lola A. Fashoyin‐Aje(Center for Drug Evaluation and Research), Richard Pazdur(United States Food and Drug Administration), Julia A. Beaver(Center for Drug Evaluation and Research)
Cited by 567
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k